Alex Goldberg

Expedia Inc. (NASDAQ:EXPE) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/10/2014 -- Equity Profile Report expands its NASDAQ Active Stock Watch List adding Expedia Inc. (NASDAQ:EXPE) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Expedia Inc. (NASDAQ:EXPE) together with its subsidiaries, operates as an online travel company in the United States and internationally is currently down (-0.51%) on 1,057,039 shares traded. Expedia Inc. (NASDAQ:EXPE) is currently down (-2.58%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Expedia Inc. (NASDAQ:EXPE)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally is currently up (+0.97%) on 897,619 shares traded after Regeneron Pharm two-year results from Phase 3 VISTA trial of EYLEA Injection for the treatment of diabetic macular edema showed sustained improvement in vision. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is currently up (+99.14%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com